For Rectal Cancer, Adjuvant 5-FU-Based Chemo Does Not Improve Survival
the Cancer Therapy Advisor take:
Adjuvant fluorouracil-based chemotherapy does not improve survival or distant recurrences in patients with rectal cancer, according to a recent study published in The Lancet Oncology.
However, adjuvant chemotherapy may have some benefit in disease-free survival and distant recurrence for those patients with a tumor 10 to 15 cm from the anal verge.
Researchers led by Anne Breugom, MD, and Marloes Swets, MD, of Leiden University Medical Centre in the Netherlands compiled information from online databases in order to identify European randomized, controlled, phase 3 trials comparing observation with adjuvant chemotherapy after preoperative radiotherapy and surgery for patients with non-metastatic rectal cancer.
They conducted a meta-analysis of four trials that included data from 1,196 patients with stage II or III disease and who had resection.
The researchers found no significant difference in overall survival between patients who received adjuvant chemotherapy and those who underwent observation.
However, in subgroup analyses, patients with a tumor 10 to 15 cm from the anal verge had an improved disease-free survival when treated with adjuvant chemotherapy compared to observation.
“Further studies of preoperative and postoperative treatment for this subgroup of patients are warranted,” the authors concluded.
Adjuvant fluorouracil-based chemotherapy does not improve survival or distant recurrences in patients with rectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
- Age-adjusted Comorbidity Predicts Survival in Laryngeal Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Role of miR-125a-5p Clarified in Bladder Cancer